explore -WSS

explore

author：leisure time 2025-09-27 12:53:51 - browse：594

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA.

Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment.

The biotech, which is based in Somerville, Mass., has big plans for the next couple of years: It has another 15 drug candidates in the works and plans to introduce 10 more annually, CEO Mike Nally told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Biotech venture capitalists face new demands from investors

hotspot

focus

WSS

Think you might have Covid

Why health workers in Gaza are injured or die at high rates

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Senate committee scrutinizes Medicare Advantage brokers

CEOs share strategies for surviving biotech slump

Independent physicians launch a new lobbying group

focus

explore

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Solve the antibiotic resistance crisis with preventive drugs

ChatGPT in medicine: STAT answers readers' burning questions

Senate committee scrutinizes Medicare Advantage brokers

Trump demands the U.S. pay no more for drugs than other countries … again

Francis Collins on trust in science and how Covid communications failed

BioMarin wins approval for gene therapy to treat hemophilia A

CEOs share strategies for surviving biotech slump

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Eli Lilly expects to double planned employment in Boston center

focus

Why health workers in Gaza are injured or die at high rates

Humana cuts profit projections as Medicare Advantage costs soar

STAT Readout Newsletter: Today's biggest biotech updates

Senate committee scrutinizes Medicare Advantage brokers

The EU Joint Clinical Assessment needs to live up to its promise

FDA warns J&J's Abiomed: We will regulate your software

hotspot

explore

focus

knowledge